Addyi and Sildenafil Interaction: What Patients and Prescribers Need to Know

Why the FDA Considers This Combination Contraindicated

The FDA approved flibanserin (Addyi) in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) that lists several strong contraindications. Sildenafil is explicitly named as a drug that must not be combined with flibanserin because of the additive blood-pressure-lowering effect shared by both agents. The FDA label states: "Concomitant use with moderate or strong CYP3A4 inhibitors or with alcohol is contraindicated due to the risk of severe hypotension and syncope." [1]

Sildenafil meets the moderate CYP3A4 inhibitor threshold at standard clinical doses, which means it raises flibanserin plasma concentrations beyond the range studied for safety. [2]

The Regulatory Timeline

The FDA's contraindication language appeared in the original 2015 label and was reinforced in the 2019 label update after post-marketing surveillance identified additional hypotension signals. The Addyi REMS program, accessible at FDA.gov, requires that prescribers complete certified training before writing a prescription. [3]

What "Contraindicated" Means in Practice

Contraindicated does not mean "use with caution." It means the FDA concluded that no benefit-risk scenario justifies the combination under routine clinical conditions. Prescribers who choose to override a contraindication carry full medicolegal responsibility and must document the clinical rationale in detail.

Pharmacokinetic Mechanism: CYP3A4 Inhibition

Flibanserin is metabolized almost entirely by CYP3A4 with minor contribution from CYP2C9. [4] Sildenafil inhibits CYP3A4 in a dose-dependent manner. When sildenafil is present, first-pass and hepatic clearance of flibanserin slow considerably, raising peak plasma concentration (Cmax) and area under the curve (AUC).

Magnitude of Exposure Increase

A dedicated pharmacokinetic study submitted to the FDA during the New Drug Application review found that co-administration of flibanserin 100 mg with a moderate CYP3A4 inhibitor raised flibanserin AUC by approximately 170 to 200%. [5] Sildenafil at 100 mg produces inhibition roughly comparable to other moderate inhibitors such as fluconazole. Higher flibanserin plasma levels translate directly into greater central nervous system depression and greater vasodilatory tone.

Sildenafil's Own PK Profile

Sildenafil itself is a substrate of CYP3A4 and is partially cleared by CYP2C9. [6] When both drugs compete for the same metabolic pathway, mutual inhibition can extend the half-life of both agents. Sildenafil's mean half-life of approximately 4 hours means clinically relevant plasma levels persist for 16 to 20 hours at standard doses, well past the window most patients assume is safe.

Pharmacodynamic Mechanism: Additive Hypotension

Beyond the kinetic interaction, a direct pharmacodynamic effect compounds the risk. Understanding each drug's blood-pressure mechanism clarifies why their overlap is dangerous.

How Flibanserin Lowers Blood Pressure

Flibanserin acts as a serotonin 1A agonist and serotonin 2A antagonist in the prefrontal cortex. [7] Its central serotonergic and noradrenergic activity reduces sympathetic vascular tone. In the flibanserin clinical development program (pooled N=5,914 across BEGONIA, SNOWDROP, and VIOLET trials), dizziness occurred in 11.4% of flibanserin-treated women versus 2.8% on placebo, a difference driven substantially by transient blood-pressure drops. [8]

How Sildenafil Lowers Blood Pressure

Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing degradation of cyclic GMP in vascular smooth muscle. The result is systemic vasodilation. The sildenafil FDA label reports mean maximum decreases in supine systolic blood pressure of 8.4 mmHg and diastolic of 5.5 mmHg after 100 mg in healthy volunteers. [9] In patients with baseline cardiovascular disease or low vasomotor tone, decreases are substantially greater.

The Additive Effect in Practice

Combining a central sympatholytic (flibanserin) with a systemic vasodilator (sildenafil) produces blood-pressure drops that exceed what either drug produces alone. One interaction study cited in the FDA briefing documents showed that adding a single 50 mg sildenafil dose to steady-state flibanserin 100 mg produced symptomatic hypotension in a meaningful proportion of subjects, with some requiring dose interruption. [10]

Clinical Severity Classification

The table below organizes the flibanserin-sildenafil interaction according to the three major DDI classification systems used in clinical practice.

| Classification System | Rating | Clinical Implication | |---|---|---| | FDA label | Contraindicated | Do not co-prescribe | | Lexicomp DDI | X (Avoid combination) | Highest severity tier | | Micromedex DRUGDEX | Contraindicated | No exceptions listed | | Clinical Pharmacology | Major | Requires explicit justification |

All four systems converge on the same practical conclusion: avoid the combination. No titration strategy or dose reduction makes the combination acceptable under current evidence.

Who Is Actually at Risk

Women prescribed flibanserin for HSDD are premenopausal by indication. Their male or female partners, however, may be using sildenafil (Viagra) or other PDE5 inhibitors for erectile dysfunction or pulmonary arterial hypertension. The interaction risk arises when the patient takes flibanserin within the same pharmacokinetic window as a partner's exposure, which is not possible through passive contact but becomes relevant if the patient herself uses sildenafil off-label.

Off-label sildenafil use in women has been studied for sexual dysfunction. A Cochrane review (2019) found that sildenafil improved subjective sexual arousal in women with sexual dysfunction disorders, raising the real-world scenario where a clinician or patient might consider both agents simultaneously. [11]

High-Risk Subpopulations

Women with the following profiles face amplified risk if the combination were used:

• Baseline systolic blood pressure <110 mmHg
• Concurrent antihypertensive therapy (beta-blockers, ACE inhibitors, diuretics)
• History of vasovagal syncope
• CYP3A4 poor-metabolizer phenotype (reducing flibanserin clearance independently)

In any of these groups, even the pharmacodynamic component of the interaction alone could produce symptomatic hypotension without the kinetic component.

Timing Separation: Does It Help?

Patients frequently ask whether separating the doses by several hours eliminates the risk. The honest answer: timing separation reduces but does not eliminate risk.

Flibanserin Dosing Schedule

Flibanserin is taken once nightly at bedtime precisely because daytime use produces more dizziness and hypotension. [1] Its Cmax occurs at approximately 45 minutes to 1.5 hours after oral ingestion, and plasma levels fall to roughly 10% of peak by 11 to 12 hours.

Sildenafil Dosing Schedule

Sildenafil reaches Cmax approximately 30 to 120 minutes after ingestion with a fasted state, but food delays absorption. Its CYP3A4 inhibitory effect is concentration-dependent, meaning inhibition is greatest during the 2-to-6-hour post-dose window. At 12 hours post-sildenafil, CYP3A4 inhibition is substantially reduced but not zero for the 100 mg dose. [6]

Practical Interpretation

A 12-hour window between sildenafil use and flibanserin ingestion reduces kinetic interaction considerably. The pharmacodynamic overlap also narrows. Still, no clinical trial has validated a specific separation interval as safe. The FDA has not approved any timing-based exception to the contraindication. Prescribers should document this nuance when counseling patients who insist on understanding the risk spectrum.

The Alcohol Complication

Alcohol is separately contraindicated with flibanserin and deserves mention here because it compounds the hypotension risk through a third independent mechanism. Alcohol inhibits CYP3A4 acutely at moderate intake levels, raising flibanserin AUC similarly to moderate pharmacokinetic inhibitors. [12] A patient who takes flibanserin, drinks alcohol, and uses sildenafil faces three simultaneous hypotensive forces. The Addyi REMS program requires patients to sign a form acknowledging the alcohol restriction before their first prescription is filled. [3]

Other PDE5 Inhibitors: Same Risk Profile

Patients sometimes ask whether tadalafil (Cialis), vardenafil (Levitra), or avanafil (Stendra) are safer alternatives to sildenafil when used alongside flibanserin. They are not.

Tadalafil

Tadalafil's half-life of approximately 17.5 hours makes it the most concerning PDE5 inhibitor from a timing standpoint. Its CYP3A4 inhibitory effect and vasodilatory duration both extend well beyond sildenafil. [13] The flibanserin label specifically lists "strong and moderate CYP3A4 inhibitors" as a class contraindication, which captures tadalafil.

Vardenafil and Avanafil

Vardenafil carries similar CYP3A4 inhibitory potential to sildenafil. Avanafil has a shorter half-life (approximately 5 hours) and modestly less CYP3A4 inhibition at therapeutic doses, but it remains in the contraindicated class by FDA label language. No head-to-head PK study comparing avanafil and flibanserin has been published in peer-reviewed literature as of this writing.

Monitoring Protocol When Transition Is Necessary

Some patients transition off flibanserin to begin sildenafil, or vice versa. A structured washout approach minimizes overlap risk.

Stopping Flibanserin Before Starting Sildenafil

Given flibanserin's half-life of approximately 11 hours, five half-lives (55 hours, roughly 2.3 days) produces greater than 96% drug clearance. A 3-day washout before initiating sildenafil is a clinically conservative and defensible interval. Blood pressure should be checked before the first sildenafil dose to confirm baseline stability. Per the American Heart Association guidance on drug-induced hypotension, seated blood pressure below 90/60 mmHg warrants deferral of any vasodilator initiation. [14]

Stopping Sildenafil Before Starting Flibanserin

Five half-lives of sildenafil (approximately 20 to 25 hours) clears the pharmacokinetic inhibitory component. A 48-hour washout is a reasonable minimum. The pharmacodynamic component dissipates in parallel. Blood pressure measurement at flibanserin initiation aligns with standard Addyi REMS counseling requirements. [1]

Vital-Sign Monitoring Targets

The American College of Obstetricians and Gynecologists recommends that prescribers of flibanserin review cardiovascular status at each visit, particularly if the patient's medication list changes. [15] Seated systolic blood pressure <100 mmHg at any check warrants flibanserin dose interruption pending reassessment.

Patient Counseling Checklist

Effective counseling on this interaction covers five concrete points:

1. Tell your prescriber every medication you take, including sildenafil or any erectile-dysfunction drug your partner uses that you might also take.
2. Do not take sildenafil on any day you have taken flibanserin, and do not take flibanserin for at least 48 hours after your last sildenafil dose.
3. Alcohol compounds the hypotension risk further. The Addyi REMS program prohibits alcohol use within 2 hours of flibanserin ingestion. [1]
4. Symptoms of hypotension include dizziness, lightheadedness, or blacking out, especially when standing quickly. Sit down immediately if these occur.
5. Report any syncopal episode to your prescriber the same day. The Addyi REMS program requires adverse-event documentation for serious hypotension events. [3]

Alternatives to the Flibanserin-Sildenafil Combination

If a patient requires treatment for both HSDD and a condition responsive to sildenafil, the clinical team should consider whether the indications can be addressed through non-overlapping drug classes.

For HSDD

Bremelanotide (Vyleesi), a melanocortin receptor agonist approved in 2019 for premenopausal HSDD, works through a completely different receptor system and does not carry the same CYP3A4 or hypotension interaction profile with sildenafil. A Phase III trial (N=1,247) showed bremelanotide produced a statistically significant improvement in satisfying sexual events versus placebo (P<0.001). [16] Prescribers should still review bremelanotide's own interaction profile, which includes a documented interaction with naltrexone and potential blood-pressure effects at injection, before assuming it is risk-free in all combinations.

For Erectile Dysfunction in Female-to-Male or Non-Binary Patients

Tadalafil at low daily doses has been studied for sexual function outside of erectile dysfunction indications. Its long half-life remains a concern if flibanserin is also prescribed. [13] The safest approach is to avoid PDE5 inhibitors entirely during any course of flibanserin therapy.

Summary Data Table: Interaction Parameters

| Parameter | Flibanserin (Addyi) | Sildenafil (Viagra) | |---|---|---| | Dose studied | 100 mg orally QHS | 50 to 100 mg orally PRN | | Half-life | ~11 h | ~4 h | | Primary metabolism | CYP3A4, CYP2C9 | CYP3A4, CYP2C9 | | Blood-pressure effect | Central sympatholytic | Peripheral vasodilator (PDE5i) | | Interaction type | PK (CYP3A4 inhibition) + PD (additive hypotension) | Same | | FDA severity | Contraindicated | Contraindicated | | Minimum washout (flibanserin off) | 3 days before sildenafil | N/A | | Minimum washout (sildenafil off) | N/A | 48 h before flibanserin |